BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 34532134)

  • 1. N6-methyladenosine (m6A) regulatory gene divides hepatocellular carcinoma into three subtypes.
    Wei J; Fang DL; Zhou W; He YF
    J Gastrointest Oncol; 2021 Aug; 12(4):1860-1872. PubMed ID: 34532134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Analysis of N6-methyladenosine Modification Patterns Associated With Multiomic Characteristics of Bladder Cancer.
    Liu J; Wang J; Wu M; Zhang W; Meng L; Wang J; Lv Z; Xia H; Zhang Y; Wang J
    Front Med (Lausanne); 2021; 8():757432. PubMed ID: 35004726
    [No Abstract]   [Full Text] [Related]  

  • 3. N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment.
    Shi Y; Wang Y; Zhang W; Niu K; Mao X; Feng K; Zhang Y
    Front Endocrinol (Lausanne); 2023; 14():1153802. PubMed ID: 37469973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The m6A methylation landscape stratifies hepatocellular carcinoma into 3 subtypes with distinct metabolic characteristics.
    Shen X; Hu B; Xu J; Qin W; Fu Y; Wang S; Dong Q; Qin L
    Cancer Biol Med; 2020 Nov; 17(4):937-952. PubMed ID: 33299645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. m6A Regulator-Associated Modification Patterns and Immune Infiltration of the Tumor Microenvironment in Hepatocarcinoma.
    Li J; Wang W; Zhou Y; Liu L; Zhang G; Guan K; Cui X; Liu X; Huang M; Cui G; Sun R
    Front Cell Dev Biol; 2021; 9():687756. PubMed ID: 34277630
    [No Abstract]   [Full Text] [Related]  

  • 6. N6-methyladenosine (m6A)-mediated messenger RNA signatures and the tumor immune microenvironment can predict the prognosis of hepatocellular carcinoma.
    Shen S; Yan J; Zhang Y; Dong Z; Xing J; He Y
    Ann Transl Med; 2021 Jan; 9(1):59. PubMed ID: 33553352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. M6A regulator-mediated immune infiltration and methylation modification in hepatocellular carcinoma microenvironment and immunotherapy.
    Zhao K; Wei B; Zhang Y; Shi W; Zhang G; Wang Z
    Front Pharmacol; 2022; 13():1052177. PubMed ID: 36438800
    [No Abstract]   [Full Text] [Related]  

  • 8. N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma.
    Meijing Z; Tianhang L; Biao Y
    Front Cell Dev Biol; 2022; 10():913307. PubMed ID: 35813200
    [No Abstract]   [Full Text] [Related]  

  • 9. Analysis of N6-Methyladenosine Modification Patterns and Tumor Immune Microenvironment in Pancreatic Adenocarcinoma.
    Liu Y; Li G; Yang Y; Lu Z; Wang T; Wang X; Liu J
    Front Genet; 2021; 12():752025. PubMed ID: 35046996
    [No Abstract]   [Full Text] [Related]  

  • 10. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
    Huang X; Qiu Z; Li L; Chen B; Huang P
    Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of m6A Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration in Ovarian Cancer.
    Luo Y; Sun X; Xiong J
    Front Cell Dev Biol; 2021; 9():794801. PubMed ID: 35087835
    [No Abstract]   [Full Text] [Related]  

  • 12. N6-methyladenosine methylation modification patterns reveal immune profiling in pancreatic adenocarcinoma.
    Xu H; Yin L; Xu Q; Xiang J; Xu R
    Cancer Cell Int; 2022 May; 22(1):199. PubMed ID: 35606813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrative Analysis of m6A RNA Methylation Regulators and the Tumor Immune Microenvironment in Non-Small-Cell Lung Cancer.
    Zhu J; Jiang Y; Wang T; Wu A; Zhou T; Zhang A; Tang Y; Shen Z; Wang J; Zhou H; Shi J; Chen J
    Dis Markers; 2022; 2022():2989200. PubMed ID: 35186164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N6-methyladenosine methylation-related genes
    Wang Y; Li T; Liu H; Liang Y; Wang G; Fu G; Takatsuki M; Qu H; Jing F; Li J; Jiang M
    Ann Transl Med; 2022 Dec; 10(24):1398. PubMed ID: 36660669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive characterization of m6A methylation and its impact on prognosis, genome instability, and tumor microenvironment in hepatocellular carcinoma.
    Yin T; Zhao L; Yao S
    BMC Med Genomics; 2022 Mar; 15(1):53. PubMed ID: 35260168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. m6A Regulator-Mediated Tumour Infiltration and Methylation Modification in Cervical Cancer Microenvironment.
    Zhang W; Xiao P; Tang J; Wang R; Wang X; Wang F; Ruan J; Yu S; Tang J; Huang R; Zhao X
    Front Immunol; 2022; 13():888650. PubMed ID: 35572541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constructing and validating of m6a-related genes prognostic signature for stomach adenocarcinoma and immune infiltration: Potential biomarkers for predicting the overall survival.
    Yang J; Wu Z; Wu X; Chen S; Xia X; Zeng J
    Front Oncol; 2022; 12():1050288. PubMed ID: 36620557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. m6A regulator-mediated methylation modification highlights immune infiltration patterns for predicting risk in hepatocellular carcinoma.
    Zhou D; Wang Y; Wei W; Zhou W; Gu J; Kong Y; Yang Q; Wu Y
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3661-3680. PubMed ID: 35972694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of m6A Methylation Modification Patterns and Tumor Immune Microenvironment in Breast Cancer.
    Dong M; Shen W; Yang G; Yang Z; Li X
    Front Cell Dev Biol; 2022; 10():785058. PubMed ID: 35178386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An m6A-Related Prognostic Biomarker Associated With the Hepatocellular Carcinoma Immune Microenvironment.
    Du Y; Ma Y; Zhu Q; Liu T; Jiao Y; Yuan P; Wang X
    Front Pharmacol; 2021; 12():707930. PubMed ID: 34248650
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.